Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : $6.6 million
April 06, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb | Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 19, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb | Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable